hero image
hero image
hero image
hero image

Rapid Urine Diagnostic Platform for STIs

  • Rynd Biotech is leading a revolution in the field of rapid urine diagnosis. We specialize in providing accurate, point-of-care testing solutions and discreet at-home testing.
  • Our innovative technology aims to redefine sexually transmitted infections (STIs) management by automating diagnosis and prescription delivery upon positive test results.
  • Addressing the global STI testing market that's projected to reach $150 billion by 2030.

Our Mission

Rynd Biotech is dedicated to facilitating early detection and ongoing monitoring of urinary infections.

Our technology not only identifies symptomatic cases but also uncovers asymptomatic cases that often go unnoticed. We are working on expanding our biomarker range to include screenings for urinary tract infections (UTIs), pregnancy indicators, urology and oncology markers. This will allow for comprehensive monitoring of infection progression and more effective disease management.

1 Million

Asymptomatic STIs acquired every day1

Decreasing trend in US High School Students Reported condom use2

62%

2007

54%

2017

367 Million

New Urine Infections of Chlamydia, Gonorrhea and Trichomoniasis in 20201

1. “Sexually Transmitted Infections (STIs).”
2. “Youth Risk Behavior Survey Data Summary & Trends Report 2007-2017.”

Our Solution

Rynd Logo

Instant, Easy, and Accurate STI Testing

Rynd Biotech introduces an innovative urine diagnostics platform that is instant, portable, accurate, and easy to use.

Our device utilizes a microfluidic chip and aptamer technology to deliver results within minutes, targeting STI pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis.

Our Products

mock-image-mobile
mock-image-mobile
mock-image-mobile

Rynd Biotech's platform stands out against traditional PCR and NAAT lab-based tests, offering portability, rapid results, and quantitative data, unlike the qualitative results from conventional methods.

The app delivers not just a diagnosis but also automated prescriptions and epidemiological insights, revolutionizing both personal health management and public health monitoring.

The diagnostic device performs the quantification measurements and transmits the results through a USB-C connection to the app.

The test strips consist of microfluidics channels that allow the multiplex quantification of biomarkers in a single drop of urine.

Key Features

graph image

Quantification with 900X signal amplification per binding event for precise pathogen identification

api image

Rapid quantitative diagnosis using a single drop of urine

droplet image

Telehealth services and automated prescriptions upon request

About Us

Welcome to Rynd, where we're redefining the gold standard for urine tests. Our goal is to revolutionize access to real-time health monitoring. Join us as we change the landscape of healthcare. Together, we aim to build a healthier world, foster groundbreaking innovation, and ensure enjoyment at every step.

Co-Founders

team-member-Camille Dodd

Camille Dodd

Co Founder & CEO

team-member-Hector G. Dorta, MSc

Hector G. Dorta, MSc

Co Founder & CSO

Advisors

team-member-Julien Cousineau

Julien Cousineau

Tech Advisor

team-member-Alister Martin, M.D.

Alister Martin, M.D.

Medical Advisor

team-member-Steve Kennedy

Steve Kennedy

Financial Advisor

team-member-Matthew Karol, J.D./B.C.L

Matthew Karol, J.D./B.C.L

Legal Advisor

team-member-Michel Gaudreau

Michel Gaudreau

Strategic & Capital Raising Advisor

team-member-Ihor Boszko

Ihor Boszko

Life Sciences Commercial Advisor

Roadmap

2024

Seed round

Patent application

FDA pre-submission

Clinical Trial Protocol

First prototype

2025

-

2026

Clinical Trials

FDA 510(k) submission

FDA approval

Sales in Texas

2027+

Other targets of interest

Urine diagnostics platform

Full sale rollout

FAQs

© 2025 Rynd Biotech. All rights reserved